how many people are on glp-1 drugs The Multi-Sector Impacts of GLP-1RA GLP-1 Drugs Show Potential To
Description
9,293 Views 85 Download 1 Crossref ABSTRACT Obesity is a disease requiring treatment
C prefers a more convenient option than adding another daily injection
Currently, three of the incretin-based products are FDA approved for weight loss Wegovy (semaglutide), Saxenda (liraglutide), and Zepbound (tirzepatide)
Suter, et al
5 These guidelines align with the American Diabetes Association (ADA) standards of care which also provide strong recommendations based on robust clinical trial data supporting the cardiovascular benefits of GLP-1 RAs, particularly in patients with established cardiovascular disease and chronic kidney disease (CKD)
Some people may also benefit from other diabetes medications, such as metformin or SGLT2 inhibitors
